PTSM: Pharmaceutical Technology Sourcing and Management, Jul 11, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PTSM: Pharmaceutical Technology Sourcing and Management, Jul 11, 2012
Biologics
Biosimilars: Market Weaknesses and Strengths
By Patricia Van Arnum
Biosimilars represent an emerging niche in the biopharmaceutical market, but how strong is their true potential?
Outsourcing
Biomanufacturing Innovation
By Eric Langer
Industry wants more innovation, but can suppliers meet customer needs?
Global Feature
What is Ahead in Chemical API Manufacturing
By Patricia Van Arnum
Flow chemistry and microreactors offer an alternative to traditional batch manufacturing.
New Models in Contract Services
By Patricia Van Arnum
Sponsor companies' increasing focus on strategic outsourcing has changed the rules of the game.
Decades of Change for the Top Pharmaceutical Companies
By Patricia Van Arnum
Tracking change from spinoffs of chemical companies to life-sciences powerhouses.
A Look into the Future: The Pharmaceutical Company of 2020
By Patricia Van Arnum
How will the pharmaceutical company of 2020 be different from the pharmaceutical company of 2010? A look at emerging business models and the factors influencing the direction of the global pharmaceutical industry.
CSR and Sustainability Forum
The UN at the Sustainability Table
By Patricia Van Arnum
Highlights of UN Conference on Sustainable Development, held in Rio de Janeiro, Brazil, last month and related industry initiatives.
CSR and Sustainability in the News
A roundup of developments in corporate social responsibility (CSR) and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here